MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1
Clinical trials for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1 explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1 trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can adding another drug improve MDS treatment?
Disease control OngoingThis study compares the standard drug azacitidine alone versus azacitidine combined with either lenalidomide or vorinostat in 282 patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if any combination improves re…
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live …
Matched conditions: MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS-1
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC